Skip to main content
Scientific publications

At Day One, we use the power of leading-edge science to improve patient outcomes.

We believe timely and transparent dissemination of data from our clinical trials and other studies is essential to inform clinical decision making and to advance scientific understanding. Our comprehensive list of publications is below.
November 2022
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
van Tilburg CM, Jones DTW, Schmidt R, Avula S, Schouten-van Meeteren A, Sehested A Opocher E, Hernáiz Driever P, Witt R, Ziegler DS, Blackman SC, Zhao X,Tsao L-P,Manley P,Cox MC, Hargrave D, Witt O 2022 Society for Neuro-Oncology - Annual Meeting
2022 SNO Annual Meeting: Abstract CTNI-30
June 2022
FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors
Landi D, Ziegler DS, Franson AT, Baxter PA, Leary SES, Larouche V, Waanders AJ, van der Lugt J, McCowage G, Jabado N, Cornelio I, Blackman SC, Da Costa D, Cox MC, Witt O, Kilburn L, Hansford JR.
ASCO Annual Meeting 2022: Abstract TPS10062
November 2021
Activity of pan-RAF inhibitor DAY101 in a pediatric patient with a recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion
Offer K, McGuire M, Venetsanakos E, Blackman S, Song K, Goldfischer M, Cox M
2021 Connective Tissue Oncology Society Annual Meeting
October 2021
FIRELIGHT: DAY101-102a, a phase 2 subprotocol of DAY101 monotherapy for patients with recurrent, progressive, or refractory solid tumors with an activating BRAF gene fusion
Mehmi I, Lourdes L, Cornelio I, Blackman S, Barry E, Drexel M, Kondo A, Kummar S
18th International Congress of the Society for Melanoma Research
October 2021
Prolonged complete response to the pan-RAF inhibitor DAY101 in a patient with an NRAS-mutated acral lentiginous melanoma
Medina T, Barry E, Raju S, Blackman S, Gonzalez R
18th International Congress of the Society for Melanoma Research
April 2021
Pan-RAF inhibitor DAY101 exhibits preclinical activity in preclinical tumor models harboring BRAF alterations beyond BRAF V600E mutation
Venetsanakos E, Preigh M, Hou J, Cox MC, Blackman SC
Pan-RAF inhibitor DAY101 exhibits preclinical activity in preclinical tumor models harboring BRAF alterations beyond BRAF V600E mutation. Abstract 1481. Presented at the American Association for Cancer Research Annual Meeting, April 10-15, 2021.